The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

(2012) Michael J. Lee et al.   CELL

2D protrusion but not motility predicts growth factor–induced cancer cell migration in 3D collagen

(2012) Aaron S. Meyer et al.   JOURNAL OF CELL BIOLOGY

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib

(2012) Oana Pop et al.   Journal of Thoracic Oncology

Targeting Axl With an High-affinity Inhibitory Aptamer

(2012) Laura Cerchia et al.   MOLECULAR THERAPY

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth

(2012) Fred Harbinski et al.   Cancer Discovery

Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer

(2011) Chen-Yun Yeh et al.   BMC CANCER

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

(2011) J. E. Chaft et al.   CLINICAL CANCER RESEARCH

Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer

(2011) E. T. Roussos et al.   JOURNAL OF CELL SCIENCE

Signaling Network State Predicts Twist-Mediated Effects on Breast Cell Migration Across Diverse Growth Factor Contexts

(2011) Hyung-Do Kim et al.   MOLECULAR & CELLULAR PROTEOMICS

An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype

(2011) Irina M. Shapiro et al.   PLoS Genetics

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target

(2010) Jan-Bart M. Koorstra et al.   CANCER BIOLOGY & THERAPY

A systems view of epithelial–mesenchymal transition signaling states

(2010) Stuart Thomson et al.   CLINICAL & EXPERIMENTAL METASTASIS

Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer

(2010) A. Lapuk et al.   MOLECULAR CANCER RESEARCH

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

(2010) D Ercan et al.   ONCOGENE

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

(2010) X Ye et al.   ONCOGENE

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer

(2010) K Vuoriluoto et al.   ONCOGENE

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

(2010) J. H. Taube et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

(2009) G. Zhuang et al.   CANCER RESEARCH

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH

Epithelial-Mesenchymal Transitions in Development and Disease

(2009) Jean Paul Thiery et al.   CELL

Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells

(2009) Q.-Q. Li et al.   CLINICAL CANCER RESEARCH

BioNumbers—the database of key numbers in molecular and cell biology

(2009) Ron Milo et al.   NUCLEIC ACIDS RESEARCH

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

(2008) Stuart Thomson et al.   CLINICAL & EXPERIMENTAL METASTASIS

Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme

(2008) M. Hutterer et al.   CLINICAL CANCER RESEARCH

Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1

(2008) K-Y Tai et al.   ONCOGENE